Severe colitis while responding to ipilimumab in metastatic melanoma

Author： Slingerland Marije Nortier Johan W. R. Veenendaal Roeland A. Kapiteijn Ellen

ISSN： 0284-186X

Source： Acta Oncologica, Vol.51, Iss.6, 2012-07, pp. : 805-807

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ipilimumab: showing survival benefit in metastatic melanoma

By Minchom Anna Young Kate Larkin James

Future Oncology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1255-1264

Future Medicine

Access to resources Recommend Favorite

Realworld efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma

Oncology Letters, Vol. 11, Iss. 2, 2016-01 ,pp. : 1581-1585

Spandidos Publications

Access to resources Recommend Favorite

Anti-CTLA4 Monoclonal Antibody Ipilimumab in the Treatment of Metastatic Melanoma: Recent Findings

Recent Patents on Anti-Cancer Drug Discovery, Vol. 3, Iss. 2, 2008-06 ,pp. : 105-113

Bentham Science Publishers

Access to resources Recommend Favorite

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports

By Wilgenhof Sofie Four Stephanie Du Everaert Hendrik Neyns Bart

Cancer Investigation, Vol. 30, Iss. 10, 2012-12 ,pp. : 712-720

Informa Healthcare

Access to resources Recommend Favorite

Metastatic melanoma: Is biochemotherapy the future?

By Alexandrescu Doru Dutcher Janice Wrnik Peter

Medical Oncology, Vol. 22, Iss. 2, 2005-06 ,pp. : 101-111

Humana Press, Inc

Access to resources Recommend Favorite